Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Biosion Inc.
Headquarters: Nanjing, Jiangsu, China
Website: http://www.biosion.com/
Year Founded: 2017
Status: Private
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Feb 20, 2025
Management Tracks
Bourla becomes chair of PhRMA
Plus: Steve Worland named CEO of Atomwise and updates from Ona, Cidara and Biosion
BioCentury | Nov 23, 2024
Finance
ATB’s €54M series A among largest ever in Belgium
BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris
BioCentury | Nov 19, 2024
Politics, Policy & Law
RFK Jr. & HHS, Blenrep’s comeback, China deals: a BioCentury podcast
One editor’s take on why a Kennedy-led HHS would be disastrous for FDA, biopharma and patients
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | May 4, 2024
Discovery & Translation
Science spotlight: Biotechs discover new checkpoint target, and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Jan 10, 2024
Data Byte
TSLP mAbs for asthma behind Tezspire
At least eight mAbs in development; two also hit IL-13
BioCentury | Oct 25, 2023
Emerging Company Profile
Aiolos: going for best in class with a long-acting TSLP mAb for asthma
Start-up, which launched with a $245M series A, is taking on AstraZeneca-Amgen drug with a mAb in-licensed from China-based Hengrui
BioCentury | Apr 25, 2023
Product Development
April 24 Quick Takes: Ideaya gains on uveal melanoma data
Plus: Foghorn pauses targeted degrader study and updates from bluebird, Lilly, MaaT, Biosion
Items per page:
1 - 10 of 19